ADT1564-Rovelizumab Biosimilar-(ITGAL/CD11a/ITGB2/CD18)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1564 |
Product Name |
ADT1564-Rovelizumab Biosimilar-(ITGAL/CD11a/ITGB2/CD18)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse ITGAL antibody, anti-ITGAL antibody, anti ITGAL antibody, recombinant ITGAL, ITGAL antibody, anti-ITGAL monoclonal antibody, ITGAL antibodies, ITGAL recombinant antibody, ITGAL blocking antibody, CD11a recombinant antibody, CD11a blocking antibody, ITGB2 recombinant antibody, ITGB2 blocking antibody, CD18 recombinant antibody, CD18 blocking antibody |
|
Alias |
Hu23F2G |
Host |
CHO Cells |
Species |
Human |
Target |
ITGAL/CD11a/ITGB2/CD18 |
Gene ID |
3683 |
Isotype |
IgG4 |
Size |
1mg, 5mg |
Research Area |
Immunology |
CAS Number |
339086-79-2 |
Product Description |
Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients suffering from haemorrhagic shock. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock. |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Hickman A, et al. J Clin Invest, 2022 Jul 1. PMID 35552271
2. Liu YX, et al. Int J Clin Exp Pathol, 2015. PMID 26884833
3. Chigaev A, et al. Mol Biol Cell, 2015 Jan 1. PMID 25378583
|





